David R. Bauer

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $25 million public offering of 4,166,667 common shares of…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 2,481,781 shares of common stock for an aggregate price to the public of approximately $90 million. The…

Davis Polk advised the underwriters in connection with the $34.5 million public offering of 13,800,000 common shares of Affimed N.V. The offering included 1,800,000 common shares sold…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…

Davis Polk advised Intsights Cyber Intelligence Ltd on its $30 million funding round led by Qumra Capital. Launched in 2015 and headquartered in New York, Intsights is trusted by…